🔍

Solara Active Pharma Sciences Limited (SOLARA)

₹696.70 +7.38% last close, 16 Oct

📊 NSE: SOLARA 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📢 Latest filing: 16 Oct 2026 📝 Analysis written: 14 Dec 2025

Q2 FY27 results

Solara Active Pharma Sciences Limited reported Q2 FY27 results on 16 Oct 2026: revenue ₹417 Cr (+33.1% year on year, +9.4% on the previous quarter), and net profit ₹28.5 Cr (against a loss a year earlier); the operating margin was 18.4%.

Q2 FY27 (₹ Cr)	Value	YoY vs Q2 FY26	QoQ
Revenue	₹417	+33.1%	+9.4%
Operating profit	₹76.8	+121.2%	+24.0%
Net profit	₹28.5	from loss	+74.5%
EPS (₹)	5.92	from loss	+68.2%
Operating margin	18.4%	—	—

Turnaround: profit against a loss a year ago
Operating margin expanded 734 bps YoY
Exceptional items of ₹-4.5 Cr in the quarter

Quality of profit: the core business earned ₹32.4 Cr before tax; other income and one-off items took ₹4.0 Cr off that, leaving pre-tax profit of ₹28.5 Cr.

Share price since the results: +7.4% (close before the filing to the latest close).

Full quarterly financials → Margins & quality of profit → All Q2 FY27 results → Results calendar →

SOLARA delivery percentage and bulk deals

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 11.93% of the SOLARA shares traded on NSE were taken to delivery, against the stock's own 20-session average of 40.73%. The price rose 7.38% on unusually low delivery, so more of the move than usual was intraday trading. It traded 11.9 times its average daily volume. 2 bulk or block deals were reported in SOLARA in the last 60 days: ₹19 Cr bought and ₹19 Cr sold.

11.93%Delivery, 16 Oct

40.73%Own 20-session average

11.9×Volume vs its average

₹696.70NSE close · +7.38%

Delivery in the last 5 sessions: 50.1% · 48.8% · 50.5% · 51.3% · 11.9%

Date	Side	Counterparty	Value	Price	Quantity	Type
16 Oct	Sell	Junomoneta Finsol Private Limited	₹18.90 Cr	₹724.62	260,838	Bulk
16 Oct	Buy	Junomoneta Finsol Private Limited	₹18.87 Cr	₹724.53	260,455	Bulk

Delivery across the market →Unusual volume today →All bulk and block deals →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Solara Active Pharma Confirms Nil Deviation in ₹446.62 Cr Rights Issue Proceeds Utilization

🟡 NEUTRAL ⭐ 3/10

FUNDRAISE 📅 16 Oct 2026, 04:03 PM

Solara Active Pharma Sciences has submitted its Statement of Deviation/Variation under Regulation 32 for the quarter ended September 30, 2026. The company confirmed that there has been no deviation or variation in the utilization of proceeds from its ₹446.62 crore Rights Issue. The report was reviewed and approved by the Audit Committee without comments on October 16, 2026. CRISIL Ratings Limited acts as the monitoring agency for this fundraise.

Rights issue funds raised stand at ₹446.62 Crores
Zero deviation or variation reported in the utilization of funds
Receipt of call money noted on August 19, 2026
CRISIL Ratings Limited serves as the monitoring agency for the issue

💡 Track subsequent quarterly monitoring agency reports to ensure deployment aligns with the stated objects of the Rights Issue.

Q2 FY27 PAT Swings to ₹28.5 Cr; EBITDA Doubles to ₹76.9 Cr, Best Quarter in 5 Years

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 16 Oct 2026, 01:48 PM

Solara Active Pharma Sciences reported a strong turnaround in Q2 FY27 with revenue growing 33% YoY to ₹417.8 Cr (₹4,178 Mn) and EBITDA surging 118% YoY to ₹76.9 Cr (₹769 Mn). The company returned to profitability, reporting PAT of ₹28.5 Cr compared to a net loss of ₹10.1 Cr in Q2 FY26. Growth was propelled by the core Base API business (revenue up 37% YoY to ₹327.3 Cr) and narrowing EBITDA losses in the commodity Ibuprofen segment to ₹0.2 Cr. Net debt declined by 19% over H1 FY27 to ₹500 Cr, bringing Net Debt/EBITDA down to 1.8x from 3.2x in FY26.

Q2 FY27 revenue rose 33% YoY and 9% QoQ to INR 4,178 Mn (₹417.8 Cr)
EBITDA more than doubled YoY (+118%) to INR 769 Mn with margin expanding 720 bps to 18.4%
PAT turned positive at INR 285 Mn (₹28.5 Cr) vs a loss of INR 101 Mn in Q2 FY26
Net debt dropped 19% in H1 FY27 to INR 5,000 Mn, lowering Net Debt to EBITDA to 1.8x from 3.2x in FY26
Ibuprofen business EBITDA loss narrowed to INR 2 Mn from INR 87 Mn in Q1 FY27, reaching near-breakeven

💡 Track the outcome of the strategic review regarding the Ibuprofen business expected within the next 12 weeks, and observe margin sustainability amid raw material inflationary pressures.

Solara Active Pharma Reports Q2 FY27 Consolidated PAT of ₹28.46 Cr, Revenue Up 33% YoY to ₹417.34 Cr

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 16 Oct 2026, 01:36 PM

Solara Active Pharma Sciences reported a strong turnaround for Q2 ended September 30, 2026, with consolidated revenue from operations rising 33.1% YoY to ₹417.34 Cr compared to ₹313.54 Cr in Q2 FY26. Consolidated net profit reached ₹28.46 Cr versus a net loss of ₹10.10 Cr in the year-ago period, even after absorbing an exceptional loss of ₹4.50 Cr related to the sale of CWIP at its mothballed Vizag plant. For H1 FY27, revenue reached ₹798.94 Cr with a consolidated PAT of ₹44.77 Cr, reflecting continued operational recovery and reduced finance costs (down to ₹17.78 Cr in Q2 from ₹20.83 Cr YoY). Additionally, the company has collected ₹446.62 Cr out of its ₹449.95 Cr rights issue as of September 30, 2026.

Q2 revenue from operations increased 33.1% YoY to ₹417.34 Cr from ₹313.54 Cr
Net profit swung to ₹28.46 Cr in Q2 compared to a loss of ₹10.10 Cr in Q2 of the previous year
H1 revenue reached ₹798.94 Cr with a net profit of ₹44.77 Cr (versus ₹0.42 Cr in H1 FY26)
Booked an exceptional loss of ₹4.50 Cr regarding sale of CWIP at the mothballed Vizag plant
Raised ₹446.62 Cr against the total ₹449.95 Cr rights issue as of September 30, 2026

💡 Track the sustainability of operating margins in subsequent quarters and observe progress regarding the proposed demerger of the CRAMS and Polymers business via Synthix Global Pharma Solutions.

Solara Active Pharma Approves Fresh Final Reminder-cum-Forfeiture Notice for Rights Issue Calls

🟡 NEUTRAL ⭐ 3/10

FUNDRAISE 📅 09 Oct 2026, 05:09 PM

Solara Active Pharma Sciences announced that its Rights Issue Committee approved issuing a fresh Final Reminder-cum-Forfeiture Notice on October 09, 2026. This notice targets holders of partly paid-up Rights Equity Shares who have defaulted on the First Call Money and/or Second and Final Call Money. The company is finalizing the notice details and will intimate stock exchanges upon dispatch. This procedural step is aimed at wrapping up its past rights issue capital collection or forfeiting non-compliant shares.

Resolution passed by the Rights Issue Committee on October 09, 2026
Pertains to partly paid-up Rights Equity Shares with unpaid First or Second and Final Call Money
Detailed notice dispatch date and quantum of outstanding shares not disclosed in the filing

💡 Track the upcoming stock exchange intimation regarding dispatch dates and the quantum of unpaid shares at risk of forfeiture.

Solara Submits Demat Compliance Certificate for Q2 FY27 Ended Sep 30, 2026

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 09 Oct 2026, 03:43 PM

Solara Active Pharma Sciences Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate from Cameo Corporate Services Limited confirms that all securities received for dematerialisation during the quarter ended September 30, 2026, were processed and confirmed to depositories. The security certificates were mutilated and cancelled within the prescribed timelines. This is a standard regulatory filing with no material impact on the company's financials or operations.

Compliance certificate under Regulation 74(5) submitted for the quarter ended September 30, 2026
Issued by Registrar and Share Transfer Agent Cameo Corporate Services Limited on October 6, 2026
Submitted to BSE and NSE on October 9, 2026

💡 No action is required as this is a recurring regulatory filing. Investors should monitor upcoming board meetings for Q2 FY27 earnings announcements.

Solara Shareholders Approve Rs 480 Cr Related Party Transactions with Strides Pharma

🟡 NEUTRAL ⭐ 5/10

ROUTINE 📅 22 Sep 2026, 05:54 PM

Solara Active Pharma Sciences announced the voting results of its 9th Annual General Meeting held on September 18, 2026. All five resolutions were passed with requisite majorities, including the adoption of FY26 financial statements and the reappointment of director Mr. Arun Kumar Pillai. Notably, shareholders approved material related party transactions with Strides Pharma Science Limited for up to Rs 480 crore, which represents approximately 33.5% of Solara's TTM revenue of Rs 1,431 crore. In this resolution, interested promoter entities abstained, and 99.87% of the 78.04 lakh polled public votes were cast in favor.

Approved material related party transactions with Strides Pharma Science Limited up to Rs 480 crore.
Strides RPT approval received 99.87% votes in favor among public shareholders, with promoter group abstaining from voting.
Reappointed Mr. Arun Kumar Pillai as Non-Executive Director with 99.96% votes in favor.
Adopted standalone and consolidated financial statements for the fiscal year ended March 31, 2026.
Overall meeting attendance recorded 59 shareholders via video conferencing (15 promoter and 44 public).

💡 Track the execution and quarterly disclosures of supply arrangements with Strides Pharma Science to monitor business volume realization relative to the Rs 480 crore ceiling.

Solara Concludes 9th AGM; Seeks Approval for Rs 480 Cr Related-Party Deals with Strides

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 18 Sep 2026, 05:03 PM

Solara Active Pharma Sciences held its 9th Annual General Meeting on September 18, 2026. Key business items transacted included ordinary business and a special resolution approving material related-party transactions with Strides Pharma Science Limited up to Rs 480 crore. This proposed transaction represents approximately 33.5% of Solara's TTM revenue of Rs 1,431 crore. Final voting results and the Scrutinizer's Report will be published on or before September 22, 2026.

9th AGM conducted via video conference on September 18, 2026, between 10:30 AM and 11:40 AM IST
Approval sought for material related-party transactions with Strides Pharma Science Limited up to Rs 480 crore
Proposed Strides transactions of Rs 480 crore equate to ~33.5% of TTM revenue (Rs 1,431 crore)
Voting results to be declared on or before Tuesday, September 22, 2026
Re-appointment of Mr. Arun Kumar Pillai as Non-Executive Director tabled for approval

💡 Track the final voting results disclosure by September 22, 2026, to verify approval of the Rs 480 crore related-party transaction limit with Strides Pharma Science.

Solara Active Pharma: ₹161.92 Cr Tax Demand Dropped to Nil via Rectification Order

🟢 POSITIVE ⭐ 7/10

LEGAL 📅 28 Aug 2026, 02:41 PM

Solara Active Pharma Sciences has received a Rectification Order under Section 154 of the Income Tax Act from the IT Department for Assessment Year 2019-20. The order rectifies a previous computation error and completely drops an earlier tax demand of ₹161.92 crore down to Nil. This eliminates a substantial contingent tax overhang equivalent to ~17.5% of the company's market capitalization (₹924 crore) and ~12.9% of its net worth (₹1,256 crore). There are no adverse penalties, non-compliances, or financial impacts remaining from this demand.

Income Tax rectification order reduces tax demand of ₹161.92 crore to Nil
Relates to Assessment Year 2019-20 Demand Notice originally received on March 17, 2026
Order passed under Section 154 read with Section 147 by Assistant Commissioner of Income Tax, Thane
Demand of ₹161.92 crore represented ~17.5% of market capitalization (₹924 Cr)

💡 Monitor subsequent quarterly filings for confirmation that contingent liability disclosures reflect the cancellation of this ₹161.92 crore tax dispute.

Solara Active Pharma Submits FY26 Business Responsibility and Sustainability Report

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Aug 2026, 06:34 PM

Solara Active Pharma Sciences has submitted its statutory Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 pursuant to SEBI LODR regulations. The standalone disclosure highlights an export revenue contribution of 52% across 64 countries, with 71% of raw material inputs sourced domestically. The company reported zero voluntary or forced product recalls and zero cybersecurity breaches during the year. Employee turnover among permanent staff improved significantly to 13% in FY26 from 30% in FY25.

Exports accounted for 52% of total turnover, reaching 64 international markets in FY26
Direct sourcing within India increased to 71% of input materials, with 33% sourced from MSMEs
Reported 0 product recalls (voluntary or forced) and 0 data breach incidents during FY26
Permanent employee turnover decreased to 13% in FY26 compared to 30% in FY25

💡 This is a routine statutory ESG disclosure. Investors should focus on upcoming quarterly earnings for operational turnaround and CRAMS business traction.

Solara Issues 9th AGM Notice; Seeks Approval for ₹480 Cr RPT with Strides Pharma

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 25 Aug 2026, 06:16 PM

Solara Active Pharma Sciences has scheduled its 9th Annual General Meeting for September 18, 2026, via video conferencing. The key special business agenda includes shareholder approval for material Related Party Transactions (RPT) with Strides Pharma Science Limited up to an aggregate of ₹480 crore until the next AGM in 2027. This RPT limit represents ~33.5% of Solara's TTM revenue of ₹1,431 crore. Other standard resolutions include the adoption of FY26 financial statements and the re-appointment of director Arun Kumar Pillai.

AGM scheduled for Friday, September 18, 2026, with cut-off date set to September 11, 2026
Remote e-voting window open from September 15, 2026 (9:00 AM) to September 17, 2026 (5:00 PM)
Approval sought for material related-party transactions with Strides Pharma Science Ltd up to ₹480 crore
Approval sought for ₹4,75,000 remuneration plus expenses for Cost Auditor for FY27

💡 Eligible shareholders may review the AGM resolutions and cast their votes between September 15 and September 17, 2026, ahead of the AGM on September 18, 2026.

Solara Converts 2.79 Lakh Partly Paid Shares to Fully Paid Post Call Money Receipt

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 19 Aug 2026, 11:11 AM

Solara Active Pharma Sciences approved the conversion of 2,79,582 partly paid-up rights equity shares into fully paid-up equity shares (face value Rs 10 each) following receipt of call monies. The converted shares include 2,23,051 shares on which the second and final call of Rs 112.50 per share was paid, and 56,531 shares on which the first and final call of Rs 243.75 per share was paid. Following this conversion, the total paid-up share capital stands at Rs 48.16 Cr, comprising 4,80,81,817 fully paid equity shares and 1,68,695 partly paid shares.

Approved conversion of 2,79,582 partly paid-up rights shares into fully paid-up equity shares of face value Rs 10.
2,23,051 shares converted upon receipt of Rs 112.50 per share (Rs 3 face value + Rs 109.50 premium).
56,531 shares converted upon receipt of Rs 243.75 per share (Rs 6.50 face value + Rs 237.25 premium).
Total paid-up capital revised to Rs 48,16,16,569 comprising 4,80,81,817 fully paid equity shares.
Pending partly paid shares reduced to 59,419 (Rs 7 paid) and 1,09,276 (Rs 3.50 paid).

💡 Track subsequent listing and trading approvals for the converted 2,79,582 equity shares on BSE and NSE.

Solara Active Pharma Allots 2,250 Shares Under ESOP 2018

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 18 Aug 2026, 01:57 PM

Solara Active Pharma Sciences Limited approved the allotment of 2,250 fully paid-up equity shares of face value Rs. 10 each on August 17, 2026, pursuant to the exercise of vested employee stock options under ESOP 2018. Following the allotment, the total share count increased from 4,82,48,262 to 4,82,50,512 shares. Total paid-up equity capital rose marginally from Rs. 48,05,57,464.50 to Rs. 48,05,79,964.50. The newly issued shares rank pari-passu with existing equity shares.

Allotment of 2,250 equity shares of face value Rs. 10 each upon ESOP exercise
Total paid-up share capital increased from Rs. 48,05,57,464.50 to Rs. 48,05,79,964.50
Fully paid-up shares rose from 4,77,99,985 to 4,78,02,235
Board approval completed via circular resolution on August 17, 2026

💡 This is a routine administrative update with negligible dilution; no specific action is required.

Solara Active Pharma Sciences Revises CIO Appointment Date to August 17, 2026

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 07 Aug 2026, 03:51 PM

Solara Active Pharma Sciences has announced a one-week delay in the joining of its new Chief Information Officer (CIO), Mr. Ajit Manocha. The effective date of appointment has been revised from August 10, 2026, to August 17, 2026, due to personal reasons cited by the appointee. Mr. Manocha brings over 33 years of experience in digital transformation and technology strategy within the pharmaceutical and CRDMO sectors. This update follows the initial appointment intimation dated July 23, 2026.

Effective appointment date for Mr. Ajit Manocha revised to August 17, 2026
Delay of 7 days from the original scheduled joining date of August 10, 2026
Appointee brings over 33 years of experience in technology and Life Sciences transformation
Company maintains a TTM revenue of Rs 1369 Cr with 75% exposure to regulated markets

💡 Investors should treat this as a routine administrative update. The focus remains on the company's ability to achieve its growth target of Rs 350 Cr+ quarterly revenue and the execution of its CRAMS strategy.

Solara Q1 FY27: PAT up 55% to ₹16.3 Cr; Net Debt reduced by 22% to ₹479 Cr

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 29 Jul 2026, 11:34 AM

Solara reported its highest EBITDA and PAT in 18 quarters for Q1 FY27, with total revenue growing 20% YoY to ₹384 Cr. The turnaround is driven by the base business (non-Ibuprofen), which grew 24% YoY to ₹307 Cr with gross margins exceeding 52%. A critical development is the ₹135 Cr reduction in net debt, bringing it down to ₹479 Cr (1.9x annualized EBITDA), largely funded by ₹100 Cr from a rights issue. However, the Ibuprofen segment remains a drag with a negative 12% EBITDA margin due to pricing and supply chain pressures.

Q1 FY27 PAT reached ₹16.3 Cr, a 55% YoY increase and the highest in 18 quarters.
Net debt reduced by ₹135 Cr (22%) during the quarter to ₹479 Cr as of June 30, 2026.
Base business revenue grew 24% YoY to ₹307 Cr, maintaining a healthy 52% gross margin profile.
Ibuprofen business reported a negative 12% EBITDA margin, though showing marginal sequential improvement.
Management targets further debt reduction to approximately ₹440 Cr by March 2027.

💡 Watch for the strategic decision on the Ibuprofen business expected by the end of H1 FY27 and the company's ability to sustain 10% growth in the base business amidst raw material price volatility.

Solara Releases Q1 FY27 Earnings Call Audio Recording Following July 23 Meeting

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 23 Jul 2026, 07:17 PM

Solara Active Pharma Sciences has released the audio recording of its Q1 FY27 earnings call held on July 23, 2026. This follows a period where the company has been attempting to stabilize operations, targeting a quarterly revenue run-rate of over 350 Cr. While the company reported a net loss of 7 Cr over the trailing twelve months, the most recent reported quarter (Mar 2026) showed a profit of 9.73 Cr. Investors should focus on management's commentary regarding the 'mothballed' Vizag facility and CRAMS business progress.

Earnings call conducted on July 23, 2026, at 16:00 IST for the quarter ended June 30, 2026
Company is targeting a quarterly revenue pivot point of 350 Cr+ to enter a growth phase
TTM revenue stands at 1,369 Cr against a market capitalization of 1,839 Cr
Gross margin profile remains sensitive to competition, with a target maintenance level of 51%
Vizag facility remains mothballed pending secured CRAMS partnerships

💡 Investors should review the audio recording for specific updates on the timeline for restarting the Vizag facility and the status of new CRAMS contracts which are critical for re-rating.

View All SOLARA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates as a pure-play API business. Total income was INR 1,294.29 Cr in FY24, a marginal decline of 0.2% YoY from INR 1,466.36 Cr in FY23. Q2 FY26 revenue was INR 314 Cr, representing a 10% YoY decline from INR 347.2 Cr in Q2 FY25 and a 2% QoQ decline from INR 320.1 Cr in Q1 FY26.

Geographic Revenue Split

Regulated markets remain the primary revenue driver, contributing 75% of overall sales in Q2 FY26, compared to 77% in Q1 FY26 and 76% in Q2 FY25. This concentration in regulated markets ensures higher quality standards but increases exposure to US FDA and EMA regulatory actions.

Profitability Margins

Gross margins remained resilient at 51% in Q2 FY26, though this was a 264 bps decline QoQ due to changes in the product mix. Net profitability saw a massive recovery from a PAT loss of INR 566.96 Cr in FY24 (PAT margin -43.97%) to a positive PAT of INR 0.54 Cr in FY25.

EBITDA Margin

EBITDA margin recovered to 16.5% (INR 213.84 Cr) in FY25 from a negative 7.1% (INR -92.03 Cr) in FY24. However, Q2 FY26 EBITDA margin dropped to 11.3% (INR 35.2 Cr), a 673 bps YoY decrease from 18.0% in Q2 FY25, driven by operational disruptions and one-time costs.

Capital Expenditure

The company has focused on debt reduction and equity infusion rather than large-scale new CapEx. Net debt to equity improved from 1.1x in FY24 to 0.7x in FY25. Specific investments include upgrading Effluent Treatment Plants (ETPs) and a INR 4 Cr facility upgradation at the Mangalore site.

Credit Rating & Borrowing

CRISIL maintains a Negative/Stable outlook. Interest coverage improved significantly to 2.12x in FY25 from -0.89x in FY24. Term debt obligations are approximately INR 100-117.25 Cr per annum, with bank limit utilization high at 95.68% as of late 2023.

⚙️ Operational Drivers

Raw Materials

Key raw materials include chemical intermediates for anthelmintic, anti-malaria, and NSAID APIs. While specific chemical names are not listed, raw material procurement and inventory levels are currently planned for sales exceeding INR 350 Cr per quarter.

Import Sources

Not specifically disclosed, though the company notes significant price competition from Chinese suppliers, implying China is a major sourcing or competitive benchmark region.

Capacity Expansion

The Vizag facility is currently 'mothballed' and will only resume operations once CRAMS (Contract Research and Manufacturing Services) partnerships are secured. The Mangalore facility recently underwent an unscheduled shutdown for facility upgradation.

Raw Material Costs

Raw material costs are a significant driver of the 49% cost of goods sold (implied by 51% gross margin). Deferred deliveries of high-margin products led to an inventory buildup of raw materials, increasing current liabilities.

Manufacturing Efficiency

Operational challenges in Q2 FY26 led to deferred deliveries of products worth INR 30-35 Cr. The company is focusing on network optimization and opex leverage to improve efficiency.

📈 Strategic Growth

Expected Growth Rate

12%

Growth Strategy

The company aims to pivot from a stable phase to a growth phase by targeting quarterly revenues of INR 350 Cr+. Key strategies include expanding the CRAMS business (Vizag plant), increasing focus on the non-steroidal anti-inflammatory (NSAID) segment, and reducing debt through equity infusions and rights issues.

Products & Services

Active Pharmaceutical Ingredients (APIs) for therapeutic segments including anthelmintic, anti-malaria, anti-infective, and non-steroidal anti-inflammatory drugs (NSAIDs) like Ibuprofen.

Brand Portfolio

Solara Active Pharma Sciences.

New Products/Services

The company is granting 3,50,000 stock options under the ESOP 2024 plan to align management with new product development and business expansion goals.

Market Expansion

Focusing on increasing market share in regulated markets (currently 75% of revenue) and diversifying the API portfolio into new therapeutic segments.

Market Share & Ranking

Positioned as a key player in the global API market, particularly in specialized segments like anthelmintics and NSAIDs.

Strategic Alliances

Actively seeking partnerships for the CRAMS division to utilize the currently mothballed Vizag facility.

🌍 External Factors

Industry Trends

The API industry is seeing a shift toward 'China+1' sourcing strategies, which Solara is positioned to benefit from, provided it maintains its 'stellar compliance record' and manages its 16.5% EBITDA margin targets.

Competitive Landscape

Faces intense competition from large-scale Chinese API manufacturers and other Indian pure-play API companies.

Competitive Moat

Moat is built on management's extensive experience, a robust compliance framework, and a 75% revenue contribution from high-entry-barrier regulated markets. Sustainability depends on avoiding further operational 'one-offs'.

Macro Economic Sensitivity

Highly sensitive to global pharmaceutical demand and healthcare regulatory shifts in the US and Europe.

Consumer Behavior

Demand is driven by global pharmaceutical companies' needs for high-quality, compliant API sources for generic and branded drugs.

Geopolitical Risks

Trade barriers or increased scrutiny on Indian API manufacturing sites by foreign regulators (US FDA) pose a constant risk to the export-heavy model.

⚖️ Regulatory & Governance

Industry Regulations

Strict adherence to global cGMP standards is mandatory. Most products face inspections from the US FDA; any adverse observations (Warning Letters) can halt sales to the US market.

Environmental Compliance

Requires continuous investment in Effluent Treatment Plants (ETPs) to manage waste discharge; non-compliance poses a risk to manufacturing licenses.

Legal Contingencies

The company states there are no significant or material orders passed by regulators or courts that impact its status as a going concern as of March 31, 2025.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the frequency of 'one-off' operational disruptions (fire, unscheduled shutdowns) which have historically caused EBITDA to swing from 16.5% to -7.1%.